<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02060903</url>
  </required_header>
  <id_info>
    <org_study_id>Ha03-001</org_study_id>
    <nct_id>NCT02060903</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation</brief_title>
  <official_title>A Randomized, Double-Blind, Multicenter, Vehicle-Controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Accelovance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to assess the efficacy, safety and tolerability of a single&#xD;
      application of abametapir lotion 0.74% w/w compared to a vehicle control, when applied to the&#xD;
      scalp and hair for 10 minutes at home.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blind, multicenter, vehicle-controlled, parallel-group study in&#xD;
      subjects with active head lice infestation. The study was designed to assess the efficacy,&#xD;
      safety and tolerability of a single application of abametapir lotion 0.74% w/w compared to a&#xD;
      vehicle control, when applied to scalp and hair for 10 minutes at home.&#xD;
&#xD;
      Approximately 106 index subjects with their household members were enrolled into the study. A&#xD;
      total of approximately 318 subjects were enrolled, assuming an average of 3 members per&#xD;
      household participating in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Index Subjects Who Are Lice-free at All Follow-up Visits Through to the Day 14 Visit.</measure>
    <time_frame>14 days</time_frame>
    <description>Proportion of index subjects randomized into the study who are lice free at all follow up visits through to the Day 14 visit. The index subject of a household was the youngest person within that household with at least 3 live lice present, as assessed over a period of up to 15 minutes at the Screening Visit.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">379</enrollment>
  <condition>Head Lice Infestation</condition>
  <arm_group>
    <arm_group_label>Abametapir Lotion 0.74% w/w</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Lotion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abametapir Lotion 0.74% w/w</intervention_name>
    <description>Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.</description>
    <arm_group_label>Abametapir Lotion 0.74% w/w</arm_group_label>
    <other_name>Abametapir 0.74%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Lotion</intervention_name>
    <description>Vehicle Lotion was dispensed to subjects on Day 0 for self-administration at home on the same day.</description>
    <arm_group_label>Vehicle Lotion</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged six months of age or older.&#xD;
&#xD;
          2. Is in good general health based on medical history.&#xD;
&#xD;
          3. Has active head lice infestation at Screening as determined by a trained evaluator&#xD;
             with the exception of the male head of household who may self-assess as being&#xD;
             lice-free. Active head lice infestation is defined as at least three live lice for the&#xD;
             index subject and at least one live louse for the other household members.&#xD;
&#xD;
          4. The subject and/or their caregiver is physically able and willing to apply the&#xD;
             Investigational Product at home.&#xD;
&#xD;
          5. Belongs to a household with an eligible index subject with active head lice&#xD;
             infestation.&#xD;
&#xD;
          6. Agrees to an examination for head lice and to all visits and procedures throughout the&#xD;
             study.&#xD;
&#xD;
          7. Has signed an informed consent and/or assent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had treatment (over-the-counter ), home remedy or prescription medication) for head&#xD;
             lice within 14 days prior to Day 0.&#xD;
&#xD;
          2. Intends to use any other form of lice treatment from Day 0 through the Day 14 visit,&#xD;
             unless provided as rescue therapy to this Protocol.&#xD;
&#xD;
          3. Intends to use a lice comb from the Day 0 through the Day 14 visit unless provided as&#xD;
             rescue therapy to this Protocol.&#xD;
&#xD;
          4. Intends to cut their hair, use hair dye/bleach or have permanent wave hairstyling from&#xD;
             Day 0 through the Day 14 visit.&#xD;
&#xD;
          5. Has a household member(s) who is infested with lice but is not willing or not eligible&#xD;
             for enrollment.&#xD;
&#xD;
          6. Has a condition that, in the opinion of the Investigator, may increase the risk to the&#xD;
             subject and/or the interpretation of the data.&#xD;
&#xD;
          7. Has visible skin/scalp condition(s) that are not attributable to head lice&#xD;
             infestation, such as an erythema score that is &gt;2, blisters, vesicles which, in the&#xD;
             opinion of the investigative personnel or Sponsor, will interfere with safety and/or&#xD;
             efficacy evaluations.&#xD;
&#xD;
          8. Has eczema or atopic dermatitis of skin/scalp.&#xD;
&#xD;
          9. Has had a prior reaction to NixÂ® or products containing permethrin.&#xD;
&#xD;
         10. Receiving systemic or topical medication, which in the opinion of the Investigator,&#xD;
             may compromise the integrity of the safety and/or efficacy assessments.&#xD;
&#xD;
         11. Has received an investigational agent within 30 days prior to Day 0.&#xD;
&#xD;
         12. Does not have a known household affiliation with the household members (i.e., does not&#xD;
             stay in one household consistently, or sleeps at one place for several nights and then&#xD;
             at another place or location).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivas Sidgiddi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Reddy's Laboratories Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universal Biopharma Reserach INC</name>
      <address>
        <city>Dinuba</city>
        <state>California</state>
        <zip>93618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSRN Reserach</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haber Dermatology</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKenzie Medical Center</name>
      <address>
        <city>McKenzie</city>
        <state>Tennessee</state>
        <zip>38201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant reserach Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 11, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>September 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2020</results_first_posted>
  <disposition_first_submitted>August 25, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 25, 2015</disposition_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head Lice</keyword>
  <keyword>Hatchtech</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lice Infestations</mesh_term>
    <mesh_term>Parasitic Diseases</mesh_term>
    <mesh_term>Mite Infestations</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Abametapir Lotion 0.74% w/w</title>
          <description>Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.&#xD;
Abametapir Lotion 0.74% w/w</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Lotion</title>
          <description>Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.&#xD;
Vehicle Lotion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="192"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="185"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The All Randomized Subjects population consisted of all subjects randomized into the study</population>
      <group_list>
        <group group_id="B1">
          <title>Abametapir Lotion 0.74% w/w</title>
          <description>Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.&#xD;
Abametapir Lotion 0.74% w/w</description>
        </group>
        <group group_id="B2">
          <title>Vehicle Lotion</title>
          <description>Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.&#xD;
Vehicle Lotion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="187"/>
            <count group_id="B2" value="192"/>
            <count group_id="B3" value="379"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.28" spread="12.11"/>
                    <measurement group_id="B2" value="16.58" spread="13.93"/>
                    <measurement group_id="B3" value="16.43" spread="13.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="321"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="304"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="372"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Index Subjects Who Are Lice-free at All Follow-up Visits Through to the Day 14 Visit.</title>
        <description>Proportion of index subjects randomized into the study who are lice free at all follow up visits through to the Day 14 visit. The index subject of a household was the youngest person within that household with at least 3 live lice present, as assessed over a period of up to 15 minutes at the Screening Visit.</description>
        <time_frame>14 days</time_frame>
        <population>The ITT population consisted of all 108 index subjects who were enrolled and randomized in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Abametapir Lotion 0.74% w/w</title>
            <description>Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.&#xD;
Abametapir Lotion 0.74% w/w</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Lotion</title>
            <description>Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.&#xD;
Vehicle Lotion</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Index Subjects Who Are Lice-free at All Follow-up Visits Through to the Day 14 Visit.</title>
          <description>Proportion of index subjects randomized into the study who are lice free at all follow up visits through to the Day 14 visit. The index subject of a household was the youngest person within that household with at least 3 live lice present, as assessed over a period of up to 15 minutes at the Screening Visit.</description>
          <population>The ITT population consisted of all 108 index subjects who were enrolled and randomized in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events will be collected from the start of treatment until 14 days following IP treatment (approximately 15 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Abametapir Lotion 0.74% w/w</title>
          <description>Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.&#xD;
Abametapir Lotion 0.74% w/w</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Lotion</title>
          <description>Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.&#xD;
Vehicle Lotion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Srinivas Sidgiddi</name_or_title>
      <organization>Dr. Reddy's Laboratories Inc.</organization>
      <phone>9084585362</phone>
      <email>srinivassidgiddi@drreddys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

